Oppenheimer Issues Positive Forecast for AtriCure (NASDAQ:ATRC) Stock Price

AtriCure (NASDAQ:ATRC) had its price objective lifted by Oppenheimer from $36.00 to $45.00 in a report released on Thursday,Benzinga reports. They currently have an outperform rating on the medical device company’s stock.

A number of other equities research analysts have also weighed in on the stock. JMP Securities reissued a “market outperform” rating and set a $60.00 target price on shares of AtriCure in a report on Monday. Stifel Nicolaus boosted their price objective on shares of AtriCure from $36.00 to $48.00 and gave the stock a “buy” rating in a research note on Thursday. Needham & Company LLC restated a “buy” rating and issued a $51.00 price objective on shares of AtriCure in a report on Thursday. JPMorgan Chase & Co. lifted their target price on AtriCure from $40.00 to $51.00 and gave the stock an “overweight” rating in a report on Tuesday. Finally, Canaccord Genuity Group increased their price target on AtriCure from $61.00 to $66.00 and gave the company a “buy” rating in a research note on Thursday. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $51.56.

AtriCure Stock Performance

Shares of ATRC stock opened at $39.59 on Thursday. The firm has a market capitalization of $1.93 billion, a price-to-earnings ratio of -47.70 and a beta of 1.46. The company has a current ratio of 3.62, a quick ratio of 2.59 and a debt-to-equity ratio of 0.13. The business’s 50-day moving average price is $35.52 and its 200-day moving average price is $31.17. AtriCure has a 12 month low of $18.94 and a 12 month high of $43.11.

Institutional Investors Weigh In On AtriCure

Institutional investors and hedge funds have recently made changes to their positions in the business. Arcadia Investment Management Corp MI bought a new stake in AtriCure in the third quarter worth approximately $28,000. Heck Capital Advisors LLC acquired a new stake in shares of AtriCure during the 4th quarter worth approximately $60,000. Venturi Wealth Management LLC increased its stake in shares of AtriCure by 1,337.6% in the 4th quarter. Venturi Wealth Management LLC now owns 2,257 shares of the medical device company’s stock valued at $69,000 after acquiring an additional 2,100 shares in the last quarter. KBC Group NV increased its stake in shares of AtriCure by 65.3% in the 4th quarter. KBC Group NV now owns 2,360 shares of the medical device company’s stock valued at $72,000 after acquiring an additional 932 shares in the last quarter. Finally, R Squared Ltd acquired a new position in shares of AtriCure during the 4th quarter valued at $89,000. Institutional investors own 99.11% of the company’s stock.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.